Proxima Supper Series

🍽 The Proxima Supper Series 🍽 Brought to you by Wilson Sonsini
🗓 Thursday, May 7th | 6–9pm ET
Often, healthcare doesn't move fast and break things. It moves slowly and carefully. Through regulatory cycles, reimbursement battles, and clinical adoption curves that test the most seasoned founders.
At our next Supper Series, we're sitting down with two investors who've seen it all up close for a conversation about what it really takes to scale from healthcare startup to exit: Julie Wolf, Partner at 2048 Ventures and Shelby Newsad, Partner at Compound VC (bios below). We'll also be joined by Jennifer Fang, Partner at Wilson Sonsini.

✅ Join us for an off-the-record conversation that you don't want to miss. RSVP now as seating is extremely limited.

SPECIAL GUEST SPEAKER BIO'S
Shelby Newsad (Compound VC): Shelby is committed to facilitating step-change technologies in bio and health and also sees incredible potential in broadening the the use-cases and efficiency in these sectors. Before investing at Compound, they’ve worked as a bioscience researcher across plant sciences (PhD, University of Cambridge), neuroscience (National Institutes of Health), and drug discovery (Helmholtz Institute). As a former researcher and technologist at heart, Shelby loves getting deep into the tech with founders and has >20 active bio and health theses. They’re dedicated to being a super high context and helpful thought partner for companies building in bio and health.
Julie Wolf (2048 Ventures) Julie Wolf is a Partner at 2048 Ventures, where she leads biotech and healthcare verticals. She is an investor in more than 50 startups, and is interested in platform technologies and founders transforming human health. Before 2048 ventures, Julie was Chief Science Officer and a member of the founding investment team at SOSV’s IndieBio New York. Prior to entering her investment career she worked in scientific research, communications, and biotech entrepreneurship. She holds a Ph.D. in Microbiology, Immunology, and Cancer Biology from the University of Minnesota and completed her postdoctoral fellowship at Albert Einstein College of Medicine.
Jennifer Fang (Wilson Sonsini) Jennifer Fang is a partner in the Boston office of Wilson Sonsini Goodrich & Rosati. She helps innovative start-ups grow into successful enterprises by providing counsel to the founders, management teams, and boards and by handling the legal and strategic business issues and transactions that arise at each stage. She is experienced in negotiating and executing a variety of corporate transactions, including conversions, spinouts, debt and equity financings, public offerings, PIPEs, mergers and acquisitions, and joint ventures. She also counsels venture capital, growth capital, and strategic investors with respect to their investment transactions and their existing portfolio companies. Her practice focuses on companies that can improve patient lives and healthcare through innovations and advances, including in gene editing, cell therapy, novel therapeutics, synthetic biology, proteomics, diagnostics, bioinformatics, medical devices, and research and manufacturing tools and processes. Jennifer has been recognized by various publications and organizations for her work in the life sciences industry. Chambers USA notes she is increasing recognized for her work advising emerging life sciences companies on a wide range of corporate matters, including financings, IPOs, and M&A. Jennifer was also honored with the “Best Under 40” award by the National Asian Pacific American Bar Association (NAPABA), which highlighted her work with growing start-ups to enterprises, and named a “Top Woman of Law” and a "Go-To Business Lawyer" by Massachusetts Lawyers Weekly.